Arcus Biosciences (RCUS) Competitors $10.04 +0.19 (+1.88%) Closing price 06/10/2025 03:59 PM EasternExtended Trading$10.02 -0.02 (-0.20%) As of 06/10/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RCUS vs. PTCT, CYTK, RNA, KRYS, SRPT, MRUS, ACAD, ACLX, SWTX, and RAREShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include PTC Therapeutics (PTCT), Cytokinetics (CYTK), Avidity Biosciences (RNA), Krystal Biotech (KRYS), Sarepta Therapeutics (SRPT), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. PTC Therapeutics Cytokinetics Avidity Biosciences Krystal Biotech Sarepta Therapeutics Merus ACADIA Pharmaceuticals Arcellx SpringWorks Therapeutics Ultragenyx Pharmaceutical Arcus Biosciences (NYSE:RCUS) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking. Do analysts recommend RCUS or PTCT? Arcus Biosciences currently has a consensus target price of $24.13, suggesting a potential upside of 139.81%. PTC Therapeutics has a consensus target price of $63.75, suggesting a potential upside of 22.94%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90PTC Therapeutics 1 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.64 Which has more volatility and risk, RCUS or PTCT? Arcus Biosciences has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Which has stronger valuation & earnings, RCUS or PTCT? Arcus Biosciences has higher earnings, but lower revenue than PTC Therapeutics. Arcus Biosciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$141M7.55-$307M-$4.19-2.40PTC Therapeutics$1.77B2.32-$626.60M$6.517.97 Does the MarketBeat Community favor RCUS or PTCT? PTC Therapeutics received 378 more outperform votes than Arcus Biosciences when rated by MarketBeat users. However, 65.57% of users gave Arcus Biosciences an outperform vote while only 62.15% of users gave PTC Therapeutics an outperform vote. CompanyUnderperformOutperformArcus BiosciencesOutperform Votes20065.57% Underperform Votes10534.43% PTC TherapeuticsOutperform Votes57862.15% Underperform Votes35237.85% Do institutionals & insiders have more ownership in RCUS or PTCT? 92.9% of Arcus Biosciences shares are held by institutional investors. 12.3% of Arcus Biosciences shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to RCUS or PTCT? In the previous week, PTC Therapeutics had 3 more articles in the media than Arcus Biosciences. MarketBeat recorded 10 mentions for PTC Therapeutics and 7 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.54 beat PTC Therapeutics' score of 0.25 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is RCUS or PTCT more profitable? PTC Therapeutics has a net margin of -50.32% compared to Arcus Biosciences' net margin of -102.66%. PTC Therapeutics' return on equity of 0.00% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-102.66% -45.59% -22.38% PTC Therapeutics -50.32%N/A -16.44% SummaryArcus Biosciences beats PTC Therapeutics on 10 of the 18 factors compared between the two stocks. Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$1.07B$6.86B$5.58B$19.78BDividend YieldN/A2.50%5.27%3.85%P/E Ratio-3.208.9127.3735.69Price / Sales7.55263.74414.2345.90Price / CashN/A65.8538.2517.51Price / Book1.636.697.164.83Net Income-$307M$143.74M$3.23B$1.02B7 Day Performance0.30%11.78%6.50%2.27%1 Month Performance21.50%20.94%15.27%5.78%1 Year Performance-37.52%9.61%32.69%14.58% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences2.7904 of 5 stars$10.04+1.9%$24.13+140.4%-37.7%$1.06B$141M-3.19500Analyst RevisionGap UpPTCTPTC Therapeutics3.2198 of 5 stars$51.69-0.8%$63.75+23.3%+37.6%$4.10B$1.77B-8.701,410Analyst RevisionCYTKCytokinetics4.073 of 5 stars$33.13+2.6%$70.92+114.1%-36.2%$3.96B$19.22M-6.16250Trending NewsAnalyst ForecastAnalyst RevisionRNAAvidity Biosciences2.2662 of 5 stars$32.66-9.9%$67.62+107.0%+24.0%$3.94B$8.93M-11.34190Trending NewsAnalyst ForecastHigh Trading VolumeKRYSKrystal Biotech4.5785 of 5 stars$136.08-0.6%$211.13+55.1%-21.8%$3.93B$333.45M45.51210Analyst RevisionSRPTSarepta Therapeutics4.8483 of 5 stars$39.71-7.7%$122.61+208.8%-68.1%$3.90B$2.23B31.77840High Trading VolumeMRUSMerus2.9553 of 5 stars$54.91-2.3%$85.83+56.3%+5.9%$3.80B$54.73M-13.9037ACADACADIA Pharmaceuticals3.6139 of 5 stars$22.30+1.5%$26.79+20.1%+49.2%$3.73B$996.28M28.59510Analyst RevisionACLXArcellx2.2651 of 5 stars$66.86-1.8%$111.33+66.5%+23.1%$3.68B$76.81M-94.1780Positive NewsAnalyst RevisionSWTXSpringWorks Therapeutics1.5416 of 5 stars$46.75-0.1%$52.57+12.5%+16.9%$3.52B$219.67M-13.43230Positive NewsHigh Trading VolumeRAREUltragenyx Pharmaceutical3.8369 of 5 stars$37.04-0.3%$88.77+139.7%-10.6%$3.50B$590.69M-5.841,310Analyst Revision Related Companies and Tools Related Companies PTC Therapeutics Competitors Cytokinetics Competitors Avidity Biosciences Competitors Krystal Biotech Competitors Sarepta Therapeutics Competitors Merus Competitors ACADIA Pharmaceuticals Competitors Arcellx Competitors SpringWorks Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RCUS) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RCUS Stock Free RCUS Stock Alerts